Targeting HTLV-1 Tax: Towards a Therapeutic Strategy for HTLV-1- Associated Diseases

by | Nov 5, 2026 | Publications

Curr Top Med Chem. 2026 Oct 30. doi: 10.2174/0115680266448515261028095459. Online ahead of print.

ABSTRACT

Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that belongs to the family Retroviridae and the genus Deltaretrovirus. HTLV-1 infection is linked to acute and chronic illnesses, including adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and other inflammatory disorders. This overview focuses on the molecular biology of HTLV-1, with particular emphasis on viral structure and genome organization, as well as the roles of key viral proteins in replication and pathogenesis. Special attention is given to the viral regulatory proteins Tax and HTLV-1 basic leucine zipper factor (HBZ), which drive cellular transformation, immune dysregulation, viral persistence, and disease progression. This review examines the oncogenic role of the Tax protein and its potential contribution to the immunopathogenesis of HAM/TSP. Furthermore, it summarizes current and novel therapeutic strategies against HTLV-1-associated diseases, focusing on antiretroviral therapy, immunomodulatory approaches, and Tax-targeted therapies. Challenges in clinical translation and limitations of current treatments are also discussed. This review covers most facets of HTLV-1 biology, pathogenesis, and treatment strategies, with the overall message that more studies are warranted for effective targeted therapies and disease management.

PMID:42983924 | DOI:10.2174/0115680266448515261028095459

Other publications you may be interested in…

HTLV-1 Disease

HTLV-1 Disease

HTLV-1 Disease Abstract The years 2020 and 2021 will remain memorable years for many reasons [...]. Click here to...

read more